Search Intelligence

“Admitting no liability is standard corporate defense, but a £26m payout explicitly acknowledges the severe financial liability of mishandling health data.”

“The industry loves talking about AGI, but for now they're just trying to figure out how to stop paying engineers to manually label thousands of lung X-rays.”

“Thyme Care is using its navigation software as a wedge to roll up the far more lucrative clinical trial and biosimilar supply chains.”

“Over-engineering a toothbrush with computer vision proves tech companies have completely run out of actual problems to solve.”

“Continuous dual-sensor tracking will force legacy glucose monitoring platforms to upgrade or lose market share to integrated metabolic devices.”

“Regeneron locks down a highly specialized medical market where palliative care was previously the only option.”

“Appointing an internal domestic policy director to lead the FDA means the White House wants zero institutional friction when executing its health agenda.”

“This computational modeling transitions psychiatric genetics from hunting isolated variants to mapping coordinated biological networks.”

“The executive order fundamentally alters decades of established pediatric immunization protocols as the US faces a significant resurgence in preventable viral outbreaks.”

“The discovery of measurable brain damage provides a concrete biomarker for long COVID, validating symptoms for millions of patients and opening pathways for targeted clinical trials.”

“The industry's spent the last year trying to build one omniscient model, but the real moat is wiring thousands of narrow bots together to argue until they figure a cure out.”

“This acquisition rapidly expands their ophthalmology portfolio to target a severe disease that currently lacks any approved clinical options.”

“Slapping speed caps on micro-mobility hardware does nothing when riders are still forced onto roads built for two-ton cars.”

“Merging medical research under the chief growth officer proves the company is abandoning expensive in-house scientific discovery to focus purely on acquiring external assets and squeezing profit from its existing biodefense portfolio.”

“Wall Street hits the panic button instantly whenever a health scare gets anywhere near Chipotle.”

“Outsourcing national healthcare infrastructure to private vendors while promising full data isolation doesn't work in practice.”

“Taking Lantheus private is just a brute-force play to own the entire nuclear medicine supply chain without answering to public shareholders.”